The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Open accessAbstract
Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC.Methods We undertook the open-label, randomised phase 3 EURTAC trial at 42 hospitals in France, Italy, and Spain. Eligible participants were adults (> 18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ≥ 6 months before study entry was allowed). We randomly allocated participants (1:1) according to a computer-generated allocation schedule to receive oral erlotinib 150 mg per day or 3 week cycles of standard intravenous chemotherapy of cisplatin 75 mg/m(2) on day 1 plus docetaxel (75 mg/m(2) on day 1) or gemcitabine (1250 mg/m(2) on days 1 and 8). Carboplatin (AUC 6 with docetaxel 75 mg/m(2) or AUC 5 with gemcitabine 1000 mg/m(2)) was allowed in patients unable to have cisplatin. Patients were stratified by EGFR mutation type and Eastern Cooperative Oncology Group performance status (0 vs 1 vs 2). The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. We assessed safety in all patients who received study drug (≥ 1 dose). This study is registered with ClinicalTrials.gov, number NCT00446225.Findings Between Feb 15, 2007, and Jan 4, 2011, 174 patients with EGFR mutations were enrolled. One patient received treatment before randomisation and was thus withdrawn from the study; of the remaining patients, 86 were randomly assigned to receive erlotinib and 87 to receive standard chemotherapy. The preplanned interim analysis showed that the study met its primary endpoint; enrolment was halted, and full evaluation of the results was recommended. At data cutoff (Jan 26, 2011), median PFS was 9·7 months (95% CI 8·4-12·3) in the erlotinib group, compared with 5·2 months (4·5-5·8) in the standard chemotherapy group (hazard ratio 0·37, 95% CI 0·25-0·54; p < 0·0001). Main grade 3 or 4 toxicities were rash (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the chemotherapy group), neutropenia (none vs 18 [22%]), anaemia (one [1%] vs three [4%]), and increased amino-transferase concentrations (two [2%] vs 0). Five (6%) patients on erlotinib had treatment-related severe adverse events compared with 16 patients (20%) on chemotherapy. One patient in the erlotinib group and two in the standard chemotherapy group died from treatment-related causes.Interpretation Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR mutations in patients with NSCLC and for treatment of mutation-positive patients with EGFR tyrosine-kinase inhibitors.Funding Spanish Lung Cancer Group, Roche Farma, Hoffmann-La Roche, and Red Temática de Investigacion Cooperativa en Cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“have shown improved efficacy and tolerability compared with chemotherapy in numerous phase III trials”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [32]
In the citing paper
“In clinical trials, the incidence of all-grade liver injury due to different smallmolecule targeted drugs such as tyrosine kinase inhibitors is reportedly 5-55% [144-149].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [147]
In the citing paper
“Afterwards, studies revealed that the reduced sensitivity to gefitinib or erlotinib in NSCLC was linked to EGFR-specific activating mutations.112–116”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [116]
In the citing paper
“The third-generation EGFR-TKIs include the WZ4002, CO-1686, AZD9291 and HM61713 inhibitors, which have demonstrated tumour responses in >50% of patients with the EGFR T790M mutation.8–12”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [9]
In the citing paper
“Eight randomised controlled phase III trials (table 1) have demonstrated that first-generation or second-generation EGFR-TKIs represent the best first-line treatment option in patients with advanced NSCLC whose tumours harbour EGFR mutations, when compared with chemotherapy, because they significantly improved the RR and progression-free survival (PFS).4–11”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [9]
In the citing paper
“Unfortunately, whilst patients with EGFRm+ tumors typically show good initial responses to first generation TKIs, most patients who respond to therapy ultimately develop disease progression after about 9-14 months of treatment (7-11).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [10]
In the citing paper
“Across clinical trials of first-line targeted therapy for oncogene-addicted subgroups of NSCLC, rates of objective response [G] typically range between 50% and 83% and complete responses [G] are rare; in addition, some patients exhibit de novo resistance16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [18]
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [18]
In the citing paper
“The magnitude of the improvement in progression-free survival observed in the current study is similar to that observed in studies of EGFR-mutation-positive tumors treated with firstline EGFR tyrosine kinase inhibitors.[24][25][26]”
From First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer (2014) · cites this paper as [25]
In the citing paper
“EGFR exon 19 deletions and EGFR exon 21 L858R represent the vast majority of EGFR activating mutations, and are exquisitely sensitive to approved EGFR TKIs such as erlotinib, gefitinib, and afatinib”
From Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) · cites this paper as [2]
In the citing paper
“acquired resistance develops after a median of 9 to 13 months [2][3][4]”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [3]
In the citing paper
“Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations4–6.”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [4]
In the citing paper
“Patients with classical EGFR mutations (L858R or exon 19 deletions (Ex19del)) show marked improvements in clinical outcomes when treated with first-, second- or third-generation tyrosine kinase inhibitors (TKIs)4–6,11.”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [4]
In the citing paper
“One potential limitation of the current diagnostic approach of testing only for common exon 19 and 21 mutations, as was done in the EURTAC or OPTIMAL studies, 4,5 is that such an approach might miss identifying a number of patients who could have some benefit from EGFR TKI treatment.”
From Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations (2016) · cites this paper as [5]
In the citing paper
“a strikingly long survival compared to median OS of 19–28 months with first- or second-generation EGFR TKIs[17–19].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [19]
In the citing paper
“Several randomized clinical trials have demonstrated that EGFR TKIs are more effective, as measured by response rate (RR) and progression free survival (PFS), than chemotherapy when used as initial systemic treatment for advanced EGFR mutant NSCLC (1, 4–9).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [4]
In the citing paper
“Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective clinical therapies for EGFR mutant advanced non small cell lung cancer (NSCLC) patients (1–4).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [4]
In the citing paper
“The extension of approval of Erlotinib for patients harboring EGFR mutations, in addition to the previous indication for unselected patients with NSCLC after at least one chemotherapeutic line, was obtained after the publication of two large phase III trials conducted in Asia [65] and Europe [66], providing the definitive demonstration of superiority of an EGFR TKI over standard first-line”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [66]
In the citing paper
“Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment.5–12”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [8]
In the citing paper
“Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment.5–12”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [7]
In the citing paper
“Resistance to conventional EGFR-TKIs develops after a median of 10 to 12 months and is most commonly mediated by an acquired mutation, T790M1-5.”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [3]
In the citing paper
“Several studies have consistently demonstrated that the EGFR TKIs (gefitinib, erlotinib and afatinib) produce higher RRs, longer PFS and improve QoL compared with standard platinum-based doublet chemotherapy in patients with good PS (PS 0-2), whose tumour harbours an activating (sensitising) EGFR mutation [105-112].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [112]
In the citing paper
“In one small study, there was a PFS benefit with erlotinib (9.7 v 5.2 months; HR, 0.37; 95% CI, 0.25 to 0.54; P < .001); OS had not been reached by the time of publication.29”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [29]
In the citing paper
“Since the publication of the ASCO 2009 guideline and the ASCO EGFR provisional clinical opinion,59 results from seven trials of first-line EGFR TKIs for patients with EGFR mutations have been published.11,13,29,31,34,36,40”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [29]
In the citing paper
“It is now well established that lung cancers harboring these EGFR mutations are highly responsive to single-agent EGFR inhibitors with RECIST response rates of ~55%–75% (Mok et al., 2009; Rosell et al., 2012; Sequist et al., 2013b).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Rosell et al., 2012
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Self-citation
Research works printed but not linked: 1
- International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA) version 13.0 (accessed Aug 2, 2010).
Cited by
Sorted by citations
Items 401–500 of 1,020
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations
Tissot, C., Couraud, S., Tanguy, R., Bringuier, P., Girard, N., & Souquet, P.-J. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.11.006 · Cited by 138
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression
Tavernari, D., Battistello, E., Dheilly, E., Petruzzella, A. S., Mina, M., Sordet‐Dessimoz, J., Peters, S., Krueger, T., Gfeller, D., Riggi, N., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1274 · Cited by 138
Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches
da Silva, S. D., Hier, M., Mlynarek, A., Kowalski, L. P., & Alaoui‐Jamali, M. A. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00149 · Cited by 138
Remón, J., Morán, T., Majem, M., Reguart, N., Dalmau, E., Márquez-Medina, D., & LIANES, P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.002 · Cited by 137
Self-citationYun, J., Hong, M. H., Kim, S., Park, C.-W., Kim, S., Yun, M. R., Kang, H. N., Pyo, K., Lee, S. S., Koh, J. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2906 · Cited by 137
Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
Tian, X., Gu, T., Lee, M., & Dong, Z. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188645 · Cited by 137
Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity
Chougule, A., Prabhash, K., Noronha, V., Joshi, A., Thavamani, A., Chandrani, P., Upadhyay, P., Utture, S., Desai, S. R., Jambhekar, N. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076164 · Cited by 136
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study
Nosaki, K., Satouchi, M., Kurata, T., Yoshida, T., Okamoto, I., Katakami, N., Imamura, F., Tanaka, K., Yamane, Y., Yamamoto, N., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.007 · Cited by 136
Chemotherapy remains an essential element of personalized care for persons with lung cancers
Hellmann, M. D., Li, B., Chaft, J. E., & Kris, M. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw271 · Cited by 136
Coleman, N., Hong, L., Zhang, J., Heymach, J. V., Hong, D. S., & Le, X. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100319 · Cited by 136
BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
Nguyen‐Ngoc, T., Bouchaab, H., Adjei, A. A., & Peters, S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000644 · Cited by 135
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Tomasini, P., Walia, P., Labbé, C., Jao, K., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0084 · Cited by 135
Normanno, N., Denis, M. G., Thress, K. S., Ratcliffe, M., & Reck, M. (2016) · Oncotarget · doi:10.18632/oncotarget.13915 · Cited by 135
The circulating transcriptome as a source of cancer liquid biopsy biomarkers
Solé, C., Arnaiz, E., Manterola, L., Otaegui, D., & Lawrie, C. H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.003 · Cited by 136
Liang, W., Wu, X., Fang, W., Zhao, Y., Yang, Y., Hu, Z., Xue, C., Zhang, J., Zhang, J., Ma, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085245 · Cited by 134
Leighl, N. B. (2012) · Current Oncology · doi:10.3747/co.19.1114 · Cited by 134
Wang, M., Yang, J. C.-H., Mitchell, P. L., Fang, J., Camidge, D. R., Nian, W., Chiu, C.-H., Zhou, J., Zhao, Y., Su, W.-C., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1615 · Cited by 133
EGFR mutation status on brain metastases from non-small cell lung cancer
Hsu, F., Caluwé, A. D., Anderson, D., Nichol, A., Toriumi, T., & Ho, C. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.004 · Cited by 133
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., Carbone, D. P., Gerstner, G. J., Lerner, R. E., Rubin, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30561-7 · Cited by 133
Nussinov, R., Jang, H., Tsai, C., & Cheng, F. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006658 · Cited by 134
Li, J., Yuan, S., Norgard, R. J., Yan, F., Sun, Y. H., Kim, I., Merrell, A. J., Sela, Y., Jiang, Y., Bhanu, N. V., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0519 · Cited by 136
Nedaplatin: a cisplatin derivative in cancer chemotherapy
Shimada, M., Kigawa, J., & Itamochi (2013) · Cancer Management and Research · doi:10.2147/cmar.s35785 · Cited by 133
Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers
Litvak, A. M., Paik, P. K., Woo, K. M., Sima, C. S., Hellmann, M. D., Arcila, M. E., Ladanyi, M., Rudin, C. M., Kris, M. G., & Riely, G. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000344 · Cited by 132
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Moya‐Horno, I., Viteri, S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017745012 · Cited by 134
Self-citationEGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., Lococo, F., Russo, P., Mainini, A. F., Bonifati, L. G., et al. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.4609 · Cited by 131
Yu, H. A., Schoenfeld, A. J., Makhnin, A., Kim, R. Y., Rizvi, H. A., Tsui, D. W. Y., Falcon, C. J., Houck-Loomis, B. R., Meng, F., Yang, J. L., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1260 · Cited by 131
Goldberg, S. B., Oxnard, G. R., Digumarthy, S., Muzikansky, A., Jackman, D. M., Lennes, I. T., & Sequist, L. V. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0168 · Cited by 130
The Evolution of Therapies in Non-Small Cell Lung Cancer
Boolell, V., Alamgeer, M., Watkins, D. N., & Ganju, V. (2015) · Cancers · doi:10.3390/cancers7030864 · Cited by 130
Wang, Z., Chen, R., Wang, S., Zhong, J., Wu, M., Zhao, J., Duan, J., Zhuo, M., An, T., Wang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110780 · Cited by 130
Johnson, M. L., Yu, H. A., Hart, E. M., Weitner, B. B., RADEMAKER, A. W., Patel, J. D., Kris, M. G., & Riely, G. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7328 · Cited by 130
Lee, J. J.-K., Shin, J. Y., Kim, S., Lee, S., Park, C. C., Kim, J. Y., Koh, Y., Keam, B., Min, H. S., Kim, T. M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt127 · Cited by 130
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer
Sakakibara, R., Inamura, K., Tambo, Y., Ninomiya, H., Kitazono, S., Yanagitani, N., Horiike, A., Ohyanagi, F., Matsuura, Y., Nakao, M., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.002 · Cited by 130
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131
EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.06 · Cited by 131
Self-citationSkin problems and EGFR-tyrosine kinase inhibitor
Kozuki, T. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv207 · Cited by 129
Targeted Therapy and Immunotherapy for Lung Cancer
Naylor, E. C., Desani, J., & Chung, P. K. (2016) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2016.02.011 · Cited by 129
Gallant, J., Sheehan, J. H., Shaver, T. M., Bailey, M., Lipson, D., Chandramohan, R., Brewer, M. R., York, S. J., Kris, M. G., Pietenpol, J. A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0654 · Cited by 128
Clinical Analysis and Interpretation of Cancer Genome Data
Allen, E. M. V., Wagle, N., & Levy, M. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7215 · Cited by 128
Jänne, P. A., Ou, S.-H. I., Kim, D.-W., Oxnard, G. R., Martins, R., Kris, M. G., Dunphy, F., Nishio, M., O'Connell, J., Paweletz, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70461-9 · Cited by 127
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
Jorge, S. E., Kobayashi, S. S., & Costa, D. B. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20144099 · Cited by 127
Solassol, I., Pinguet, F., & Quantin, X. (2019) · Biomolecules · doi:10.3390/biom9110668 · Cited by 129
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
Juchum, M., Günther, M., & Laufer, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.002 · Cited by 126
Stinchcombe, T. E., Janne, P. A., Wang, X., Bertino, E. M., Weiss, J. M., Bazhenova, L. A., Gu, L., Lau, C. J., Paweletz, C. P., Jaslowski, A. J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1847 · Cited by 126
Adenosquamous carcinoma of the lung
Li, C., & Lu, H. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s164574 · Cited by 125
Yamamoto, N., Seto, T., Nishio, M., Goto, K., Yamamoto, N., Okamoto, I., Yamanaka, T., Tanaka, M., Takahashi, K., & Fukuoka, M. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.020 · Cited by 125
The impact of the Cancer Genome Atlas on lung cancer
Chang, J. T.-H., Lee, Y. M., & Huang, R. S. (2015) · Translational research · doi:10.1016/j.trsl.2015.08.001 · Cited by 125
Yoshida, T., Ishii, G., Goto, K., Neri, S., Hashimoto, H., Yoh, K., Niho, S., Umemura, S., Matsumoto, S., Ohmatsu, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0846 · Cited by 125
State of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine
Nishino, M., Hatabu, H., Johnson, B. E., & McLoud, T. C. (2014) · Radiology · doi:10.1148/radiol.14122524 · Cited by 124
Circulating tumor DNA detection in lung cancer patients before and after surgery
Guo, N., Lou, F., Ma, Y., Li, J., Yang, B., Chen, W., Ye, H., Zhang, J.-B., Zhao, M.-Y., Wu, W., et al. (2016) · Scientific Reports · doi:10.1038/srep33519 · Cited by 124
Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
Gregg, J. P., Li, T., & Yoneda, K. Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.14 · Cited by 124
Gristina, V., Malapelle, U., Galvano, A., Pisapia, P., Pepe, F., Rolfo, C. D., Tortorici, S., Bazan, V., Troncone, G., & Russo, A. D. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101994 · Cited by 124
Self-citationLee, V. H.-F., Tin, V. P., Choy, T., Lam, K. O., Choi, C., Chung, L.-P., Tsang, J. W. H., Ho, P., Leung, D. K., Ma, E. S. K., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f684a · Cited by 123
Westwood, M. E., Joore, M. A., Whiting, P. F., van Asselt, A. D. I., Ramaekers, B. L. T., Armstrong, N., Misso, K., Severens, J. L., & Kleijnen, J. (2014) · Health Technology Assessment · doi:10.3310/hta18320 · Cited by 123
Buettner, R., Wolf, J., & Thomas, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9867 · Cited by 123
The clinical utility of tumor mutational burden in non-small cell lung cancer
Greillier, L., Tomasini, P., & Barlési, F. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.08 · Cited by 123
Development of synthetic lethality in cancer: molecular and cellular classification
Li, S., Topatana, W., Juengpanich, S., Cao, J., Hu, J., Zhang, B., Ma, D., Cai, X., & Chen, M. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00358-6 · Cited by 123
Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
Hirsch, F. R., Janne, P. A., Eberhardt, W., Cappuzzo, F., Thatcher, N., Pirker, R., Choy, H., Kim, E. S., Paz-Ares, L. G., Gandara, D. R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ed0ff · Cited by 122
Self-citationTong, Y., Liu, Y., Zheng, H., Zheng, L., Liu, W., Wu, J., Ou, R., Zhang, G., Li, F., Hu, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8920 · Cited by 122
Targeted therapy for non-small-cell lung cancer: past, present and future
Forde, P. M., & Ettinger, D. S. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.47 · Cited by 123
Chen, G., Feng, J., Zhou, C., Wu, Y.-L., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt012 · Cited by 121
Espósito, A., Bardelli, A., Criscitiello, C., Colombo, N., Gelao, L., Fumagalli, L. A. M., Minchella, I., Locatelli, M., Goldhirsch, A., & Curigliano, G. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.003 · Cited by 121
Roengvoraphoj, M., Tsongalis, G. J., Dragnev, K. H., & Rigas, J. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.001 · Cited by 121
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
Agulnik, M., Nelson, Ziehr, & Johnson, J. R. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s23165 · Cited by 121
Mazières, J., Brugger, W., Cappuzzo, F., Middel, P., Frosch, A., Bāra, I., Klingelschmitt, G., & Klughammer, B. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.016 · Cited by 122
YAP promotes erlotinib resistance in human non-small cell lung cancer cells
Hsu, P., You, B., Yang, Y., Zhang, W., Wang, Y., Xu, Z., Dai, Y., Liu, S., Yang, C., Li, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10458 · Cited by 121
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
Shaw, A. T., Varghese, A. M., Solomon, B., Costa, D. B., Novello, S., Mino-Kenudson, M. A., Awad, M. M., Engelman, J. A., Riely, G. J., Monica, V., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds242 · Cited by 120
Kohsaka, S., Petronczki, M. P., Solca, F., & Maemondo, M. (2018) · Future Oncology · doi:10.2217/fon-2018-0736 · Cited by 123
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
Fang, W., Huang, Y., Hong, S., Zhang, Z., Wang, M., Gan, J., Wang, W., Guo, H., Wang, K., & Zhang, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5820-0 · Cited by 120
Tong, L., Ding, N., Tong, X., Li, J., Zhang, Y., Wang, X., Xu, X., Ye, M., Li, C., Wu, X., et al. (2019) · Theranostics · doi:10.7150/thno.34070 · Cited by 120
Zhao, H., Yao, W., Min, X., Gu, K., Yu, G., Zhang, Z., Cui, J., Miao, L., Zhang, L., Yuan, X., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.006 · Cited by 123
Lin, C., Chen, X., Li, M., Liu, J., Qi, X., Yang, W., Zhang, H., Cai, Z., Dai, Y., & Ouyang, X. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.02.002 · Cited by 119
Leprieur, E. G., Duménil, C., Julié, C., Giraud, V., Dumoulin, J., Labrune, S., & Chinet, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.041 · Cited by 119
Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy
Chalela, R., Curull, V., Enríquez-Rodríguez, C. J., Pijuán, L., Bellosillo, B., & Gea, J. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.20 · Cited by 119
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 120
Mok, T. S. K., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Chawla, A., Rosell, R., Corral, J., Migliorino, M. R., et al. (2020) · Drugs · doi:10.1007/s40265-020-01441-6 · Cited by 120
Self-citationLee, S. M., Lewanski, C. R., Counsell, N., Ottensmeier, C. H. H., Bates, A. T., Patel, N., Wadsworth, C., Ngai, Y., Hackshaw, A. K., & Finn, C. F. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju151 · Cited by 118
Montor, W. R., Salas, A. R. O. S. E., & de Melo, F. H. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0792-2 · Cited by 118
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 119
Sullivan, I., & Planchard, D. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2016.00076 · Cited by 119
The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
Patel, P. H., Palma, D. A., McDonald, F., & Tree, A. C. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.05.015 · Cited by 116
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115
Furrukh, M. (2013) · Sultan Qaboos University medical journal · doi:10.12816/0003255 · Cited by 117
Lung cancer molecular epidemiology in China: recent trends.
Zhou, C. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.09.01 · Cited by 115
Quantitative proteomics in lung cancer
Cheung, C. H. Y., & Juan, H. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0343-y · Cited by 117
50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer
Wakelee, H. A., Kelly, K. L., & Edelman, M. J. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.177 · Cited by 114
Shi, L., Tang, J., Li, T., & Liu, Z. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.016 · Cited by 115
Sorensen, S. F., Demuth, C., Weber, B., Sørensen, B. S., & Meldgaard, P. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.08.001 · Cited by 114
Baik, C. S., Myall, N. J., & Wakelee, H. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0458 · Cited by 114
Incidence and consequences of bone metastases in lung cancer patients
Kuchuk, M., Addison, C., Clemons, M. J., Kuchuk, I., & Wheatley‐Price, P. (2013) · Journal of bone oncology · doi:10.1016/j.jbo.2012.12.004 · Cited by 114
Karampeazis, A., Voutsina, A., Souglakos, J., Kentepozidis, N., Giassas, S., Christofillakis, C., Kotsakis, A., Papakotoulas, P., Rapti, A., Agelidou, M., et al. (2013) · Cancer · doi:10.1002/cncr.28132 · Cited by 113
Menis, J., Hasan, B., & Besse, B. (2014) · European Respiratory Review · doi:10.1183/09059180.00004214 · Cited by 113
Gao, J., Li, H.-R., Jin, C., Jiang, J., & Ding, J. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02075-1 · Cited by 113
Strategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 112
Taverna, S., Giallombardo, M., Bazo, I. G., Carreca, A. P., Castiglia, M., Chacartegui, J. J., Araújo, A., Alessandro, R., Pauwels, P., Peeters, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7638 · Cited by 112
Self-citationAwad, M. M., Leonardi, G. C., Kravets, S., Dahlberg, S. E., Drilon, A. E. D. C., Noonan, S. A., Camidge, D. R., Ou, S. I., Costa, D. B., Gadgeel, S. M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.011 · Cited by 112
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Nilsson, M. B., Yang, Y., Heeke, S., Patel, S. A., Poteete, A., Udagawa, H., Elamin, Y. Y., Moran, C. A., Kashima, Y., Arumugam, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.007 · Cited by 112
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
Dao, J., Conway, P., Subramani, B., Meyyappan, D., Russell, S., & Mahadevan, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713219 · Cited by 112
Stewart, E., Mascaux, C., Pham, N., Sakashita, S., Sykes, J. R., Kim, L., Yanagawa, N., Allo, G., Ishizawa, K., Wang, D. Y. Q., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1492 · Cited by 112
Jakobsen, K. R., Demuth, C., Sørensen, B. S., & Nielsen, A. L. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.04.07 · Cited by 112
Reardon, D. A., Wen, P. Y., & Mellinghoff, I. K. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou232 · Cited by 111
Metadata
- Authors
- Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M. A., Terrasa, J., Muñoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J. L., Sanchez, J. J., Molina, M. A., Taron, M., & Paz-Ares, L.
- Affiliations
- Institut Català d'Oncologia (ES)
- Centre François Baclesse (FR)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Policlinico Umberto I (IT)
- Hospital Clínico Universitario de Valencia (ES)
- Hôpital Pontchaillou (FR)
- Hospital Son Llatzer (ES)
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" (IT)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Hospital Universitario Son Dureta (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Hospital Clínico Universitario Lozano Blesa (ES)
- Centre Hospitalier du Mans (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- La Maddalena (IT)
- Hospital Universitario Nuestra Señora de Candelaria (ES)
- Centre Hospitalier de Mulhouse (FR)
- Centro di Riferimento Oncologico (IT)
- Hospital Universitario Miguel Servet (ES)
- Sapienza University of Rome (IT)
- Clinica Rotger (ES)
- Pivotal (Spain) (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Corresponding author
- Rosell, Rafael
- ORCID
- Rosell, Rafael
- Carcereny, Enric
- Gervais, Radj
- Felip, Enriqueta
- Cobo, Manuel
- Garrido, Pilar
- Longo, Flavia
- Insa, Amelia
- Corre, Romain
- Altavilla, Giuseppe
- Provencio, Mariano
- Valdivia, Javier
- Isla, Dolores
- Molinier, Olivier
- Gebbia, Vittorio
- Bearz, Alessandra
- Artal, Angel
- Cortesi, Enrico
- Rolfo, Christian
- Queralt, Cristina
- Paz-Ares, Luis
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 13
- Issue
- 3
- Pages
- 239-246
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2111662961
- Cited by
- 5,489
- References
- 23
- Citations by year
- 2026: 92 · 2025: 169 · 2024: 216 · 2023: 269 · 2022: 367 · 2021: 422 · 2020: 441 · 2019: 440 · 2018: 498 · 2017: 534 · 2016: 509 · 2015: 537 · 2014: 448 · 2013: 401 · 2012: 138
- FWCI
- 392.78
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- erlotinib, EGFR-mutant non-small cell lung cancer, first-line therapy, exon 19 deletion, L858R mutation, cisplatin, docetaxel, gemcitabine, carboplatin, progression-free survival, targeted therapy, European patients, drug safety, adverse events, treatment discontinuation, EGFR tyrosine kinase inhibitors
- MeSH terms
- Erlotinib Hydrochloride, Docetaxel, Gemcitabine, Administration, Oral, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Drug Administration Schedule, Europe, Exons, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Prospective Studies, Quinazolines, Time Factors, Chi-Square Distribution, Proportional Hazards Models, Carboplatin, Treatment Outcome, Disease-Free Survival, Patient Selection, Taxoids, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Precision Medicine, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
